Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics

Blood

Volumn 93, Issue 3, 1999, Pages 1032-1037

  Garcia Sanz R ^a   Orfao A ^a   Gonzalez M ^a   Tabernero, M D ^a   Blade J ^a   Moro, M J ^a   Fernandez Calvo J ^a   Sanz, M A ^a   Perez Simon J A ^a   Rasillo, A ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN A; LACTATE DEHYDROGENASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; PLASMA CELL LEUKEMIA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0344142354     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.3.1032.403a15_1032_1037     Document Type: Article

References (33)

1. San Miguel JF, García-Sanz R, González M, Orfão A: Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol 8:735, 1995
2. Bennet JM, Catowsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick H, Sultan C: Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 42:567, 1989
3. Kyle RA, Maldonado JE, Bayrd ED: Plasma cell leukemia. Report on 17 cases. Arch Intern Med 133:813, 1974
4. Noel P, Kyle RA: Plasma cell leukemia: An evaluation of response to therapy. Am J Med 83:1062, 1987
5. Baim BJ: Blood Cells: A Practical Guide. Oxford, UK, Blackwell Science, 1995
6. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R: Primary plasma cell leukaemia. Br J Haematol 88:754, 1994
7. San Miguel JF, González M, Gascón A, Moro MJ, Hernández JM, Ortega F, Jiménez R, Guerras L, Romero M, Casanova F, Sanz MA, Sânchez J, Portero JA, Orfão A: Immunophenotype heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Br J Haematol 77:185, 1991
8. San Miguel JF, García-Sanz R, González M, Moro MJ, Hernández JM, Ortega F, Borrego D, Carnero M, Casanova F, Jiménez R, Portero JA, Orfão A: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448, 1995
9. Chronic Leukemia-Myeloma Task Force, National Cancer Institute: Proposed guidelines for protocol studies in plasma cell myeloma. Cancer Chemother 4:145, 1973
10. Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, González Brito G, Hernández-Martin J, Fernández-Calvo J, Rubio D, Ortega F, Jiménez R, Colominas P, Faura MV, Font L, Tortosa J, Domingo A, Fontanillas M, Rozman C, Estapé C: Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients. J Clin Oncol 11:1165, 1993
11. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842, 1975
12. San Miguel JF, González M, Gascón A, Moro MJ, Hernández JM, Ortega F, Jiménez R, Guerras L, Romero M, Casanova F, Sanz MA, Sánchez J, Portero JA, Orfão A: Lymphoid subsets and prognostic factors in multiple myeloma. Br J Haematol 80:305, 1991
13. González M, San Miguel JF, Gascón A, Moro MJ, Hernández JM, Ortega F, Jiménez R, Guerras L, Romero M, Casanova F, Sanz MA, Portero JA, Orf̃o A: Increased expression of natural killer-associated and activated antigens in multiple myeloma. Am J Hematol 39:84, 1992
14. García-Sanz R, Orfão A, González M, Moro MJ, Hernández JM, Bŕez A, Borrego D, Carnero M, Casanova E, Jimenez R, Portero JA, San Miguel JF: Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 93:81, 1996
15. Orfão A, García-Sanz R, López-Berges MC, Vidriales MB, González M, Caballero MD, San Miguel JF: A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 17:332, 1994
16. Ocqueteau M, Orfão A, Almeida J, Bladé J, González M, García-Sanz R, Berges MC, Moro MJ, Hernández J, Escribano L, Caballero MD, Rozman M, San Miguel JF: Immunophenotype of plasma cells from "monoclonal gammopathy of undetermined significance" (MGUS) patients. Am J Pathol 152:1655, 1998
17. García-Sanz R, Orfão A, González M, Moro MJ, Hernández JM, Ortega F, Borrego D, Carnero M, Casanova F, Jiménez R, Portero JA, San Miguel JF: Prognostic implications of DNA aneuploidy in a series of 156 untreated MM patients. Br J Haematol 90:106, 1995
18. Tabernero MD, San Miguel JF, García-Sanz R, Nájera ML, García-Isidoro M, Pérez-Simón JA, González M, Wiegant J, Raap AK, Orfão A: Incidence of chromosome numerical changes in multiple myeloma A FISH analysis using 15 chromosome specific probes. Am J Pathol 149:161, 1996
19. Norusis MJ: SPSS Base System User's Guide SPSS 40 for the Macintosh. Chicago, IL, SPSS Inc, 1990
20. Ruiz-Argüelles GJ, San Miguel JF: Cell surface markers in multiple myeloma. Mayo Clin Proc 69:684, 1994
21. Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Frutiger V, Richter L: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1, Leu-19). Blood 76:377, 1990
22. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M: Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 84:2597, 1994
23. Shimazaki C, Gotoh H, Ashihara E, Oku N, Inaba T, Murakami S, Itoh K, Ura Y, Nakagawa M, Fujita N: Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia. Am J Hematol 39:159, 1992
24. Morgan RJ, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR: Detection of hypodiploidy using multi-parameter flow cytometric analysis: A prognostic indicator in multiple myeloma. Am J Hematol 30:195, 1989
25. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K: Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 66:338, 1985
26. Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernândez JM, San Miguel JF, Orfào A: Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 91:3366, 1998
27. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer J: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
28. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jager U, Heinz R: Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55:3854, 1995
29. Sawyer JR, Waldron JA, Jagannath S, Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41, 1995
30. Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T: Improved cytogenetics in multiple myeloma. Blood 9:2490, 1995
31. Woodruff RK, Malpas JS, Paxton AM, Lister TA: Plasma cell leukemia: A report on 15 patients. Blood 8:839, 1978
32. Kosmo MA, Gale RP: Plasma cell leukemia. Semin Hematol 24:202, 1987
33. Bernasconi C, Castelli G, Pagnucco G, Brusamolino E: Plasma cell leukemia: A report on 15 patients. Eur J Haematol 43:76, 1989 (suppl 51)